[Comorbidities affecting abiraterone treatment in patients with metastatic castration-resistant prostate cancer: a meta- analysis].
1/5 보강
[AIM] Optimizing the treatment of metastatic prostate cancer is important for reducing mortality.
- 연구 설계 meta-analysis
APA
Budai B, Fekete B, et al. (2026). [Comorbidities affecting abiraterone treatment in patients with metastatic castration-resistant prostate cancer: a meta- analysis].. Magyar onkologia, 70(1), 53-68.
MLA
Budai B, et al.. "[Comorbidities affecting abiraterone treatment in patients with metastatic castration-resistant prostate cancer: a meta- analysis].." Magyar onkologia, vol. 70, no. 1, 2026, pp. 53-68.
PMID
41819062 ↗
Abstract 한글 요약
[AIM] Optimizing the treatment of metastatic prostate cancer is important for reducing mortality. Therefore, it is essential, among others, to know the predictive markers of abiraterone acetate (AA) treatment in metastatic castration-resistant prostate cancer (mCRPC). We aimed to clarify the predictive factors of AA treatment of mCRPC patients, and particularly the predictive role of comorbidities and co-medication based on meta-analysis of published data.
[METHODS] Meta-analysis of the results of multivariate analysis found in 120 publications examining at least 100 cases.
[RESULTS] Besides clear predictors of progression-free and overall survival, opioid use, pain, cerebrovascular diseases, dyslipidemia, statin treatment, bisphosphonate/antiresorptive treatment and metabolic syndrome significantly affect the risk of progression and survival.
[CONCLUSIONS] Since the analysis of comorbidities is based on relatively few observations, further studies are needed to clarify the predictive impact of comorbidities and co-medication in order to improve the effectiveness of treatment in mCRPC in an individualized manner.
[METHODS] Meta-analysis of the results of multivariate analysis found in 120 publications examining at least 100 cases.
[RESULTS] Besides clear predictors of progression-free and overall survival, opioid use, pain, cerebrovascular diseases, dyslipidemia, statin treatment, bisphosphonate/antiresorptive treatment and metabolic syndrome significantly affect the risk of progression and survival.
[CONCLUSIONS] Since the analysis of comorbidities is based on relatively few observations, further studies are needed to clarify the predictive impact of comorbidities and co-medication in order to improve the effectiveness of treatment in mCRPC in an individualized manner.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.